Post‐transplant lymphoproliferative disorders with naso‐ and oropharyngeal manifestation. (30th July 2015)

• Record Type: Journal Article
• Authors: Akbas, Ayla; Tiede, Christina; Lemound, Juliana; Maecker‐Kolhoff, Britta; Kreipe, Hans; Hussein, Kais
• Is Part Of: Transplant international. Volume 28:Number 11(2015:Nov.)
• Page Start: 1299
• Page End: 1307
• Publication Date: 2015-07-30
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; 617.95405
• DOI: 10.1111/tri.12632
• Languages: English
• ISSNs: 0934-0874

Abstract

<abstract abstract-type="main" id="tri12632-abs-0001"> <title>Summary</title> <p>The nasopharyngeal/oropharyngeal lymphatic tissues represent the anatomical site of Epstein–Barr virus (EBV) entry. Post‐transplant lymphoproliferative disorders (PTLD) are often associated with EBV, but little is known about the characteristics of nasopharyngeal/oropharyngeal mass‐forming PTLD. Retrospective evaluation of our own PTLD database (<italic>n</italic> = 79) and the PubMed<sup>®</sup> database (<italic>n</italic> = 61) has been performed. Sinonasal/oro‐/nasopharyngeal lymphatic masses were early lesions (<italic>n</italic> = 54/140, 38.5%), polymorphic PTLD (<italic>n</italic> = 32/140, 23%), monomorphic B‐PTLD (<italic>n</italic> = 47/140, 33.5%) and T‐PTLD (<italic>n</italic> = 7/140, 5%). One‐fourth of lesions manifested as masses in the Waldeyer's ring, and in two‐thirds of cases, swelling of tonsils was related to manifestation of benign early lesions. Tonsil infiltration by polymorphic PTLD and monomorphic PTLD was present in one‐third of cases. Extratonsillar masses were mainly monomorphic PTLD. Meta‐analysis of our data in combination with previously published data revealed that lung transplantation and young patients are at a higher risk for earlier manifestation of monomorphic PTLD. Therapy is similar to PTLD therapy strategies, in general reduced immunosuppression and chemotherapy for polymorphic and monomorphic PTLD, and diagnostic and therapeutic surgical gross tumour resection of tonsillar/adenoid lesions. In summary, it is relevant for the clinical differential diagnosis that oro‐/nasopharyngeal aggressive PTLD manifested in ~30% as tonsillar masses and >90% at extratonsillar sites.</p> </abstract>